Should ultrapure dialysate be part of standard therapy in hemodialysis?

Seminars in Dialysis

Volumn 24, Issue 4, 2011, Pages 426-427

  Canaud, Bernard ^a   Granger Vallée, Alexandre ^b  

^a Nephrology   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID;

HUMAN; NOTE; RENAL REPLACEMENT THERAPY; STANDARD;

DIALYSIS SOLUTIONS; HUMANS; RENAL DIALYSIS;

EID: 80051806184     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00947.x     Document Type: Note

References (29)

1. Kessler M, et al.: European best practice guidelines. Section III. Biocompatibility. Nephrol Dial Transplant 17(Suppl 7):32-44, 2002
2. Schiffl H: High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial 24:1-4, 2011
3. Ledebo I, et al.: Defining the microbiological quality of dialysis fluid. Artif Organs 23:37-43, 1999
4. Canaud B, et al.: Water treatment for contemporary hemodialysis. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester J (eds). Replacement of Renal Function by Dialysis, 4th edn. The Netherlands: Springer, 1996. Section II:231-255
5. Kessler M, et al.: European best practice guidelines. Dialysis fluid purity. Section IV. Nephrol Dial Transplant 17(Suppl 7):45-62, 2002
6. Kawanishi H, et al.: The new standard of fluids for hemodialysis in Japan. Blood Purif 27(Suppl 1):5-10, 2009
7. Quality of dialysis fluid for hemodialysis and related therapies. ANSI/AAMI/ISO 11663: 2009
8. Rahmati MA, et al.: The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs 27:723-727, 2004
9. Arizono K, et al.: Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 22(Suppl 2):26-29, 2004
10. Panichi V, et al.: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant, 2011; doi 10.1093/ndt/GFQ802 [epub ahead of print]
11. Furuya R, et al.: Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 23:311-316, 2005
12. Schiffl H, et al.: Effects of dialysis purity on uremic dyslipidemia. Ther Apher Dial 14:5-11, 2010
13. Honda H, et al.: Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif 28:29-39, 2009
14. Tao J, et al.: Conventional versus ultrapure dialysate for lowering serum lipoprotein(a) levels in patients on long-term hemodialysis: a randomized trial. Int J Artif Organs 33:290-296, 2010
15. Schiffl H, et al.: Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17:1814-1818, 2002
16. Vilar E, et al.: Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 4:1944-1953, 2009
17. Schiffl H, et al.: Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 16:1863-1869, 2001
18. Koda Y, et al.: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997
19. Ouseph R, et al.: Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant 22:2269-2275, 2007
20. Locatelli F, et al.: Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 21:1798-1807, 2010
21. Schwalbe S, et al.: Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int 52:1077-1083, 1997
22. Lederer SR, et al.: Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 91:452-455, 2002
23. Canaud B, et al.: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 69:2087-2093, 2006
24. Jirka T, et al.: Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 70:1524, 2006
25. Vinhas J, et al.: Survival advantage of patients on haemodiafiltration is independent of dialysis dose and patient characteristics: data from a single centre. Port J Nephrol Hypert 21:287-292, 2007
26. Panichi V, et al.: Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 23:2337-2343, 2008
27. Canaud B, et al.: On-line haemodiafiltration: state of the art. Nephrol Dial Transplant 13(Suppl 5):3-11, 1998
28. Penne EL, et al.: Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. Kidney Int 76(6):665-672, 2009
29. Canaud BJ: Changing paradigms of renal replacement therapy in chronic kidney disease patients: ultrapure dialysis fluid and high-efficiency hemodiafiltration for all? Kidney Int 76:591-593, 2009